Urinary Metabolomics Validates Metabolic Differentiation Between Renal Cell Carcinoma Stages and Reveals a Unique Metabolic Profile for Oncocytomas
Autor: | Shanna A Arnold Egloff, Oluyemi S. Falegan, M. Eric Hyndman, Andries Zijlstra, Hans J. Vogel |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Pathology medicine.medical_specialty Histology Endocrinology Diabetes and Metabolism Urinary system Nuclear Magnetic Resonance lcsh:QR1-502 Chromophobe cell Malignancy urologic and male genital diseases Biochemistry Article lcsh:Microbiology 03 medical and health sciences 0302 clinical medicine Metabolomics Renal cell carcinoma medicine Oncocytoma Stage (cooking) Molecular Biology business.industry medicine.disease female genital diseases and pregnancy complications 030104 developmental biology 030220 oncology & carcinogenesis business Clear cell |
Zdroj: | Metabolites, Vol 9, Iss 8, p 155 (2019) Metabolites Volume 9 Issue 8 |
ISSN: | 2218-1989 |
Popis: | Renal cell carcinoma (RCC) is a heterogeneous malignancy which often develops and progresses asymptomatically. Benign oncocytomas are morphologically similar to malignant chromophobe RCC and distinguishing between these two forms on cross-sectional imaging remains a challenge. Therefore, RCC-specific biomarkers are urgently required for accurate and non-invasive, pre-surgical diagnosis of benign lesions. We have previously shown that dysregulation in glycolytic and tricarboxylic acid cycle intermediates can distinguish benign lesions from RCC in a stage-specific manner. In this study, preoperative fasting urine samples from patients with renal masses were assessed by ¹ H nuclear magnetic resonance (NMR). Significant alterations in levels of tricarboxylic acid cycle intermediates, carnitines and its derivatives were detected in RCC relative to benign masses and in oncocytomas vs. chromophobe RCC. Orthogonal Partial Least Square Discriminant Analysis plots confirmed stage discrimination between benign vs. pT1 (R2 = 0.42, Q2 = 0.27) and benign vs. pT3 (R2 = 0.48, Q2 = 0.32) and showed separation for oncocytomas vs. chromophobe RCC (R2 = 0.81, Q2 = 0.57) and oncocytomas vs. clear cell RCC (R2 = 0.32, Q2 = 0.20). This study validates our previously described metabolic profile distinguishing benign tumors from RCC and presents a novel metabolic signature for oncocytomas which may be exploited for diagnosis before cross-sectional imaging. |
Databáze: | OpenAIRE |
Externí odkaz: |